“Phase 3b LUMINANCE trial shows promising results for durvalumab plus chemotherapy in ES-SCLC”
The preliminary findings from the phase 3b LUMINANCE trial (NCT04774380) show that first-line treatment with durvalumab (Imfinzi) plus up to 6 cycles of platinum and etoposide is safe and well-tolerated in patients with treatment-naïve extensive-stage small cell lung cancer (ES-SCLC), with indications of clinical efficacy consistent with those seen in previous studies. Presented at the … Read more
